| アブストラクト | OBJECTIVE: To characterise patients with metabolic dysfunction-associated steatohepatitis (MASH) in England and to estimate its associated healthcare resource use (HCRU) and costs, both overall and by progression status and comorbidities. DESIGN: This was a retrospective observational study of adults with a MASH-coded primary and/or secondary care recorded diagnosis in England (2011-2020). The analysis used data from the Clinical Practice Research Datalink linked to the Hospital Episode Statistics and death registrations. Annualised all-cause and MASH-related (ie, coded as MASH, end-stage liver disease or major adverse cardiovascular event) HCRU and costs were calculated for patients with incident MASH. Subgroup analyses were conducted for patients with type 2 diabetes, overweight/obesity, cardiovascular disease or progression to cirrhosis. Comparative cost analysis was conducted between those with progressed MASH and those who did not progress. RESULTS: A total of 2696 patients were included (mean follow-up: 4 years). Incidence of MASH was estimated at 4.7 per 100 000 person-years overall and increased among patients with key comorbidities. Patients who had type 2 diabetes had greater HCRU and costs than those who did not (eg, mean 1.8 vs 1.0 all-cause inpatient admissions and pound2227 vs pound1151 all-cause inpatient costs per-patient per-year). Some patients with MASH progressed to compensated (8.6%) or decompensated cirrhosis (6.5%) during the study. HCRU and costs were substantially higher among patients who progressed than among those who did not (eg, mean 2.4 vs 1.1 all-cause inpatient admissions and pound3620 vs pound1290 all-cause inpatient costs per-patient per-year). CONCLUSION: HCRU and costs associated with MASH are higher among patients who have cardiometabolic comorbidities or who progress to advanced disease stages. Therefore, efforts to detect cases early and prevent disease progression could reduce healthcare burden. |
|---|
| ジャーナル名 | BMJ open |
|---|
| Pubmed追加日 | 2025/4/24 |
|---|
| 投稿者 | Davidson, Jennifer A; Brewer, Hannah R; Rice, Caoimhe T; Carvalho, Sara J; Kim, Yestle |
|---|
| 組織名 | CorEvitas, Cheshire, UK.;Madrigal Pharmaceuticals Inc, West Conshohocken, Pennsylvania, USA;ykim@madrigalpharma.com. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/40268491/ |
|---|
